Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTB NASDAQ:ESPR NASDAQ:ITOS NASDAQ:RGNX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$1.75-1.7%$1.80$0.51▼$2.86$97.51M-0.09158,448 shs121,453 shsESPREsperion Therapeutics$2.68+5.9%$1.67$0.69▼$3.94$540.35M0.895.23 million shs10.77 million shsITOSiTeos Therapeutics$10.15$10.15$4.80▼$17.63$448.73M1.311.51 million shsN/ARGNXREGENXBIO$9.71+3.1%$8.65$5.03▼$13.48$490.49M1.17643,702 shs609,824 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma-1.69%-15.05%-17.84%+121.10%+35.14%ESPREsperion Therapeutics+5.93%+20.72%+39.58%+119.67%+47.25%ITOSiTeos Therapeutics0.00%-0.82%+0.40%-0.20%-37.54%RGNXREGENXBIO+3.08%+8.73%+17.98%+1.04%-13.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTBConnect Biopharma$1.75-1.7%$1.80$0.51▼$2.86$97.51M-0.09158,448 shs121,453 shsESPREsperion Therapeutics$2.68+5.9%$1.67$0.69▼$3.94$540.35M0.895.23 million shs10.77 million shsITOSiTeos Therapeutics$10.15$10.15$4.80▼$17.63$448.73M1.311.51 million shsN/ARGNXREGENXBIO$9.71+3.1%$8.65$5.03▼$13.48$490.49M1.17643,702 shs609,824 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTBConnect Biopharma-1.69%-15.05%-17.84%+121.10%+35.14%ESPREsperion Therapeutics+5.93%+20.72%+39.58%+119.67%+47.25%ITOSiTeos Therapeutics0.00%-0.82%+0.40%-0.20%-37.54%RGNXREGENXBIO+3.08%+8.73%+17.98%+1.04%-13.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTBConnect Biopharma 3.50Strong Buy$7.00300.00% UpsideESPREsperion Therapeutics 2.80Moderate Buy$7.00161.19% UpsideITOSiTeos Therapeutics 2.14Hold$15.5052.71% UpsideRGNXREGENXBIO 2.83Moderate Buy$28.38192.22% UpsideCurrent Analyst Ratings BreakdownLatest CNTB, RGNX, ITOS, and ESPR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/19/2025RGNXREGENXBIOHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$34.008/13/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$7.008/8/2025RGNXREGENXBIORoyal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOutperform$21.00 ➝ $17.008/8/2025RGNXREGENXBIOBarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$50.00 ➝ $37.008/8/2025RGNXREGENXBIOChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$52.008/7/2025ITOSiTeos TherapeuticsWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetEqual Weight$12.00 ➝ $11.007/22/2025CNTBConnect BiopharmaNorthland CapmkSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/21/2025ITOSiTeos TherapeuticsPiper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold7/21/2025ITOSiTeos TherapeuticsWedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$12.00 ➝ $10.506/17/2025ESPREsperion TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$16.006/12/2025CNTBConnect BiopharmaHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$7.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTBConnect Biopharma$26.03M3.75N/AN/A$1.67 per share1.05ESPREsperion Therapeutics$332.31M1.63$0.02 per share111.55($1.97) per share-1.36ITOSiTeos Therapeutics$35M12.82N/AN/A$11.17 per share0.91RGNXREGENXBIO$83.33M5.89N/AN/A$5.24 per share1.85Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTBConnect Biopharma-$15.63MN/A0.00N/AN/AN/AN/AN/AN/AESPREsperion Therapeutics-$51.74M-$0.49N/AN/A60.20-35.84%-0.91%-28.41%11/6/2025 (Estimated)ITOSiTeos Therapeutics-$134.41M-$4.67N/AN/AN/AN/A-33.26%-28.16%11/11/2025 (Estimated)RGNXREGENXBIO-$227.10M-$3.44N/AN/AN/A-112.70%-66.95%-34.14%11/5/2025 (Estimated)Latest CNTB, RGNX, ITOS, and ESPR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q2 2025RGNXREGENXBIO-$1.13-$1.38-$0.25-$1.38$40.87 million$21.36 million8/6/2025Q2 2025ITOSiTeos Therapeutics-$1.12-$1.51-$0.39-$1.81N/AN/A8/5/2025Q2 2025ESPREsperion Therapeutics-$0.17-$0.02+$0.15-$0.02$62.55 million$82.39 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCNTBConnect BiopharmaN/AN/AN/AN/AN/AESPREsperion TherapeuticsN/AN/AN/AN/AN/AITOSiTeos TherapeuticsN/AN/AN/AN/AN/ARGNXREGENXBION/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTBConnect Biopharma0.017.247.24ESPREsperion TherapeuticsN/A1.150.76ITOSiTeos TherapeuticsN/A7.537.53RGNXREGENXBION/A3.133.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTBConnect Biopharma58.72%ESPREsperion Therapeutics47.39%ITOSiTeos Therapeutics97.16%RGNXREGENXBIO88.08%Insider OwnershipCompanyInsider OwnershipCNTBConnect Biopharma22.60%ESPREsperion Therapeutics1.70%ITOSiTeos Therapeutics14.20%RGNXREGENXBIO12.79%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTBConnect Biopharma11055.72 million43.13 millionOptionableESPREsperion Therapeutics200201.62 million198.20 millionOptionableITOSiTeos Therapeutics9044.21 million37.93 millionOptionableRGNXREGENXBIO37050.51 million44.05 millionOptionableCNTB, RGNX, ITOS, and ESPR HeadlinesRecent News About These CompaniesREGENXBIO reports positive data from Hunter syndromeSeptember 6 at 3:22 PM | msn.comRegenxbio reports ‘positive’ results from Phase I/II/III CAMPSIITE trialSeptember 6 at 3:22 PM | msn.comRegenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter SyndromeSeptember 6 at 9:07 AM | seekingalpha.comREGENXBIO Inc. $RGNX Shares Acquired by PDT Partners LLCSeptember 6 at 6:11 AM | marketbeat.comREGENXBIO Presents Positive Twelve-Month Pivotal Data from Phase I/II/III CAMPSIITE® Trial of RGX-121 for Treatment of MPS IISeptember 5 at 7:05 AM | prnewswire.comTrexquant Investment LP Purchases 308,516 Shares of REGENXBIO Inc. $RGNXSeptember 5 at 4:27 AM | marketbeat.comADAR1 Capital Management LLC Purchases 162,423 Shares of REGENXBIO Inc. $RGNXSeptember 4 at 7:42 AM | marketbeat.comHsbc Holdings PLC Sells 29,002 Shares of REGENXBIO Inc. $RGNXSeptember 4 at 3:47 AM | marketbeat.comNuveen LLC Makes New Investment in REGENXBIO Inc. $RGNXSeptember 4 at 3:25 AM | marketbeat.comREGENXBIO Inc. $RGNX Shares Sold by Jump Financial LLCSeptember 2, 2025 | marketbeat.comVanguard Group Inc. Has $24.83 Million Stock Position in REGENXBIO Inc. $RGNXAugust 31, 2025 | marketbeat.comAlphaQuest LLC Increases Stock Holdings in REGENXBIO Inc. $RGNXAugust 29, 2025 | marketbeat.comREGENXBIO to Participate in Upcoming Investor ConferencesAugust 28, 2025 | prnewswire.comAlgert Global LLC Takes $354,000 Position in REGENXBIO Inc. $RGNXAugust 27, 2025 | marketbeat.com22NW LP Makes New $4.78 Million Investment in REGENXBIO Inc. $RGNXAugust 26, 2025 | marketbeat.comLeerink Partnrs Expects Reduced Earnings for REGENXBIOAugust 23, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for REGENXBIO (NASDAQ:RGNX)August 21, 2025 | marketbeat.comVoss Capital LP Has $2.79 Million Position in REGENXBIO Inc. $RGNXAugust 21, 2025 | marketbeat.comDelay hits Regenxbio BLA reviewAugust 20, 2025 | thepharmaletter.comTREGENXBIO Inc. (NASDAQ:RGNX) Receives Average Recommendation of "Moderate Buy" from AnalystsAugust 20, 2025 | marketbeat.comREGENXBIO Inc.: REGENXBIO Announces FDA Review Extension of BLA for RGX-121 to Treat Patients with MPS IIAugust 19, 2025 | finanznachrichten.deNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCNTB, RGNX, ITOS, and ESPR Company DescriptionsConnect Biopharma NASDAQ:CNTB$1.75 -0.03 (-1.69%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$1.77 +0.02 (+1.37%) As of 09/5/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of T cell-driven inflammatory diseases. The company is building a pipeline of small molecules and antibodies using functional T cell assays to screen and discover potent product candidates against validated immune targets. Its lead product candidate is rademikibart (formerly CBP-201), an antibody designed to target interleukin-4 receptor alpha, which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis and asthma, currently under Phase 3 studies; and icanbelimod (formerly CBP-307), an oral small molecule Sphingosine 1-Phosphate Receptor 1 modulator, currently under Phase 2 clinical for the treatment of ulcerative colitis and Crohn's disease. The company was founded in 2012 and is based in San Diego, California.Esperion Therapeutics NASDAQ:ESPR$2.68 +0.15 (+5.93%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$2.69 +0.01 (+0.34%) As of 09/5/2025 07:55 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.iTeos Therapeutics NASDAQ:ITOS$10.15 0.00 (0.00%) As of 08/29/2025iTeos Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of a new generation of immuno-oncology therapeutics for people living with cancer. Its pipeline includes EOS-448, Inupadenant, and EOS-984. The company was founded by Michel Detheux in April 2012 and is headquartered in Watertown, MA.REGENXBIO NASDAQ:RGNX$9.71 +0.29 (+3.08%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$9.79 +0.08 (+0.82%) As of 09/5/2025 07:50 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy. It also develops RGX-121 for the treatment of mucopolysaccharidosis type II that is in Phase III clinical trial; RGX-111 for treating mucopolysaccharidosis type I; RGX-181 for the treatment of late infantile neuronal ceroid lipofuscinosis type II; and RGX-381 to treat the ocular manifestations of CLN2 disease. In addition, the company licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies. Further, it has a collaboration and license agreement with AbbVie Global Enterprises Ltd. to develop ABBV-RGX-314 outside the United States. REGENXBIO Inc. was incorporated in 2008 and is headquartered in Rockville, Maryland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
